Quell Therapeutics

A new story by Lauren Martz for BioCentury Inc. explores the evolving landscape of Treg cell therapy in autoimmune diseases — and asks how Treg approaches like ours at Quell might stack up against other Treg and broader cell therapy strategies.   As Lauren notes, the field is approaching a clinical inflection point – with Quell poised to deliver efficacy readouts later this year. We're proud to be featured in the article and excited by the growing momentum behind engineered Treg cell therapies. Many thanks to Lauren for the thoughtful analysis and for highlighting insights from our CEO, Iain McGill.   The full article is available on BioCentury’s platform and requires a subscription to access.   #Tregs #CellTherapy #livertransplant #AutoimmuneDiseases #Immunology #Inflammation #QuellTx

CAR Treg cell therapies have the potential to reset the immune system and restore immune tolerance across a wide range of chronic diseases driven by immune dysfunction. Alongside our partners Quell Therapeutics, we’re aiming to bring the transformative potential of CAR Treg cell therapies to patients with the highest unmet need. #Immunology #CellTherapy #WhatScienceCanDo

Huge congratulations to the winner of this year's Emerging Star of the Year Award, sponsored by HSBC Innovation Banking - well done to the team at Quell Therapeutics #EMA25 #winner

Today, we are announcing that we have achieved a second significant milestone from our strategic collaboration with AstraZeneca: the selection and licensing of a CAR-Treg candidate from our Inflammatory Bowel Disease (IBD) research program that AstraZeneca will now further develop into the clinic with Quell’s continued participation including product supply for first-in-human trials. This second milestone, which follows the first Type 1 Diabetes milestone achieved under the collaboration in November 2024, triggers a $10 million payment to Quell and underscores the rapid progress being made in this strategic alliance.    The nomination of this first IBD CAR-Treg candidate complements the advances we are making with QEL-001, our internal program in mismatched liver transplant patients, and demonstrates the potential of our powerful technology to unlock a broad opportunity across autoimmune and inflammatory diseases.

We’re looking forward to attending the European Mediscience Awards 2025 on 12 June in London and are honoured that Quell Therapeutics is selected as a finalist in the Emerging Star Award category.   Thank you to the judges for the recognition and to HSBC Innovation Banking for sponsoring this award.   Our CEO, Iain McGill and CBO, Luke Henry will be attending the event, and we’re excited to celebrate this achievement alongside those of our peers and the strength of the European life sciences ecosystem.   #EMA25 #CellTherapy #Treg #Immunology #Biotech #Innovation

Making cell therapy manufacturing scalable means balancing quality, cost and speed. For Aaron Vernon, Chief Manufacturing Officer at Quell Therapeutics, the answer lies in designing better manufacturing systems. Joining Jason C. Foster on the Ori Spotlight Podcast, he shared how eliminating bottlenecks in critical areas like cell expansion and QC testing, and optimizing facility layouts are essential for improved throughput. By designing for scale from day one, we can balance cost, quality, and efficiency to enable advanced therapies to reach millions of patients worldwide. Listen to part 1 now: 1️⃣ https://xmrrwallet.com/cmx.plnkd.in/erPACqqk #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

𝗔𝗚𝗖 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀' 𝗚𝗹𝗼𝗯𝗮𝗹 𝗖𝗲𝗹𝗹 & 𝗚𝗲𝗻𝗲 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀 𝗗𝗶𝘃𝗶𝘀𝗶𝗼𝗻 𝗽𝗿𝗼𝗱𝘂𝗰𝗲𝘀 𝗟𝗩𝗩 𝗺𝗮𝘁𝗲𝗿𝗶𝗮𝗹 𝗳𝗼𝗿 Quell Therapeutics' 𝗧-𝗿𝗲𝗴 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲𝘀. With our proprietary ProntoLVV™ platform process, our team is helping Quell create transformative treatments for immune and inflammatory disorders by using the unique properties of Tregs to restore balance in the immune system. "AGC Biologics provides the reliability, speed and efficiency we need as we prepare our Treg therapies for clinical trials. This partnership is critical as we work to address severe immune disorders and bring innovative treatments to patients. We are looking forward to working with the AGC Biologics team of experts to support our programs into clinical development." - Aaron Vernon, Chief Manufacturing Officer, Quell Therapeutics. Read the full press release by accessing the link in the comments below. #Pharma #CellandGene #Biotech #Biopharma #LifeSciences #yourfriendlyCDMOexpert

We are excited to be sharing our latest research and progress on our CAR-Treg cell therapy platform at the American Society of Gene & Cell Therapy (ASGCT) conference in New Orleans (13th-15th May):   Georgios Eleftheriadis, Senior Scientist, will deliver an oral presentation titled ‘Development of CAR-Treg Therapies for Transplantation and Autoimmunity,’ with an overview of Quell’s CAR-Treg platform and lead QEL-001 program in the Phase 1/2 LIBERATE clinical trial in liver transplantation on 14th May; 8:30-9:30am CDT.   Elmar Jaeckel, co-founder, will give an oral presentation titled ‘ENTPD3-specific CAR Regulatory T cells for Therapy of Type 1 Diabetes’ highlighting our research in T1D that is being progressed in collaboration with AstraZeneca on 15th May; 1:30-3:15pm CDT.   #CARTreg #celltherapy #immunetolerance #livertransplantation #type1diabetes

Quell Tx at #EASL2025 – Advancing Treg Science in Transplantation   We're pleased to share that Alberto Sánchez-Fueyo, one of our founders, will be presenting at the EASL Congress this week.   Alberto will present a poster presentation 'QEL-001 LIBERATE Study Expansion Cohort CAR-Treg engraftment and expansion following rATG conditioning in liver transplantation' on Friday 9th May. #QuellTherapeutics #LiverTransplantation #CellTherapy #Immunotherapy #CAR_Treg #TregScience #EASL2025 

Exciting Week Ahead at #ISCT2025! Marc Martinez-Llordella, Vice President of Biology at Quell Therapeutics will be presenting at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting in New Orleans this week.   Marc will present a poster and oral presentation 'Characterization of engineered CAR-Treg cells to induce immune tolerance in liver transplanted patients'.   We’re so proud that this work was recognized as one of the “NEW Top Scoring Emerging Immunotherapy Abstract Awards” at ISCT 2025.   #QuellTherapeutics #CellTherapy #Immunotherapy #CAR_Treg #TransplantMedicine #ISCT2025